Dialysis News and Research

Latest Dialysis News and Research

Neutrolin post marketing surveillance data presented at 52nd ERA-EDTA Congress

CorMedix Inc., a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases, today announced a presentation on Neutrolin® post marketing surveillance data at the 52nd European Dialysis and Transplant Association (ERA-EDTA) Congress.

2 Jun 2015

New data on Resverlogix RVX-208 for CKD treatment presented at ERA-EDTA Congress

Resverlogix Corp. today announced that new data on RVX-208 was presented at the ERA-EDTA Congress in London, England in a poster entitled: "Effects of RVX-208, a First-in-Class Epigenetic BET-Inhibitor, on Key Renal Parameters in Subjects with a History of CVD, and Chronic Kidney Disease (CKD); a Post-hoc Analysis of Patients from the ASSERT, SUSTAIN and ASSURE Clinical Trials."

1 Jun 2015

First European approval of drug to treat genetic kidney disease ADPKD

Otsuka Pharmaceutical Co., Ltd. announced that the European Commission has granted marketing authorisation for JINARC® (tolvaptan) for the treatment of ADPKD in adults who have chronic kidney disease (CKD) stage one to three at initiation of treatment with evidence of rapidly progressing disease

29 May 2015

Amgen announces AMG 416 Phase 3 results for treatment of secondary hyperparathyroidism in CKD patients

Amgen today announced pooled data from two pivotal Phase 3, global, randomized, placebo-controlled trials evaluating AMG 416, a novel calcimimetic, for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease (CKD) receiving hemodialysis.

29 May 2015

DaVita Clinical Research announces expansion of clinical trials capabilities in Europe

DaVita Clinical Research (DCR), a specialty contract research organization with services spanning a broad spectrum of drug and device development, today announced an expansion of its clinical trials capabilities in Europe.

28 May 2015

Ardelyx reports positive results from tenapanor Phase 2b clinical trial in IBS-C patients

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal, and metabolic diseases, today presented Phase 2b clinical trial results that demonstrated statistically significant and clinically meaningful improvement in IBS-C symptoms for tenapanor-treated patients compared to patients receiving placebo.

19 May 2015

WHO Regional Office for the Eastern Mediterranean press release: WHO delivers additional medicines and medical supplies into Yemen

WHO is also providing a shipment of anti-malaria medicines from the Global Fund to Fight AIDS, Tuberculosis and Malaria sufficient for 44 950 treatment courses of malaria...

15 May 2015

DaVita HealthCare Partners recognizes May as Employee Health Month

DaVita HealthCare Partners Inc., one of the nation's largest and most innovative health care communities, recognizes the month of May as Employee Health Month. The health of teammates is vital in helping to ensure they can provide the best quality of care for DaVita HealthCare Partners' patients.

7 May 2015

Phosphate Therapeutics reports positive results from PT20 trial in people with hyperphosphataemia

Phosphate Therapeutics Limited, a development-stage specialty pharmaceuticals company, today announces positive results from the PEACH pivotal study of PT20 in subjects with hyperphosphataemia related to dialysis dependent chronic kidney disease (DD-CKD).

7 May 2015

DaVita Way of Giving program receives Communitas Award

DaVita HealthCare Partners Inc., one of the nation's largest and most innovative health care communities, today announced that the company received a Communitas Award for its DaVita Way of Giving program.

22 Apr 2015

Upsher-Smith presents favorable data from PREVAIL OLE study of Qudexy XR capsules

Upsher-Smith Laboratories, Inc. presented data from a 52-week, open-label extension study (PREVAIL OLE) showing that Qudexy XR (topiramate) extended-release capsules offered a long-term adjunctive treatment option with a favorable tolerability profile for a high proportion of patients with refractory partial-onset seizures (POS).

21 Apr 2015

Bayshore HealthCare achieves BPSO designation

Bayshore HealthCare Ltd. is pleased to announce that it has achieved the designation of Best Practice Spotlight Organization presented by the Registered Nurses' Association of Ontario.

20 Apr 2015

NEFIGAN Trial of Nefecon for treatment of primary IgA nephropathy meets primary endpoint

Pharmalink AB, a specialty pharma company, today announces that the NEFIGAN Trial of Nefecon for the treatment of primary IgA nephropathy has fully met its primary efficacy endpoint at a planned interim analysis and been stopped early with respect to statistical analysis of the endpoint.

14 Apr 2015

Managing autosomal dominant polycystic kidney disease: an interview with Dr Richard Sandford, University of Cambridge

Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common inherited kidney diseases. It's also one of the most common reasons that people require dialysis or transplantation...

13 Apr 2015

New simeprevir clinical data to be presented at EASL's International Liver Congress 2015

Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, today announced that clinical data for simeprevir, its NS3/4A protease inhibitor for the treatment of hepatitis C virus (HCV) infection, will be presented at The International Liver Congress 2015 of the European Association for the Study of the Liver taking place in Vienna from April 22-26.

8 Apr 2015

New oral drug shows promise in patients with chronic kidney disease

Patients with chronic kidney disease may be treated with a class of medications called Renin Angiotensin Aldosterone System inhibitors (RAASI's). Although these drugs protect the heart and kidney, a significant percentage of patients develop a dangerous side effect -- high potassium levels in the blood (hyperkalemia).

31 Mar 2015

Six winners share £2 million to develop cutting-edge technology to prevent kidney disease

SIX winners, announced today, will receive a share of over £2 million as part of a Small Business Research Initiative competition aimed at developing cutting-edge technology solutions to help kidney patients.

31 Mar 2015

DaVita Kidney Care celebrates its dietitians and social workers

DaVita Kidney Care, a division of DaVita HealthCare Partners Inc. and a leading provider of kidney care services, is celebrating its more than 3,600 dietitians and social workers during March for their distinctive and important roles in patient care.

30 Mar 2015

Regulus' RG-012 receives orphan medicinal product designation in EU for treatment of Alport syndrome

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that the European Commission has granted orphan medicinal product designation for RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21") for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy.

25 Mar 2015

TVA Medical's novel hemodialysis access technique shows positive outcomes in clinical study

TVA Medical, Inc., today announced promising results from a clinical study evaluating a novel hemodialysis access technique that has the potential to revolutionize vascular access for patients with chronic kidney disease without the use of traditional open surgery.

25 Mar 2015

Dialysis News and Research

Latest Dialysis News and Research

Neutrolin post marketing surveillance data presented at 52nd ERA-EDTA Congress

New data on Resverlogix RVX-208 for CKD treatment presented at ERA-EDTA Congress

First European approval of drug to treat genetic kidney disease ADPKD

Amgen announces AMG 416 Phase 3 results for treatment of secondary hyperparathyroidism in CKD patients

DaVita Clinical Research announces expansion of clinical trials capabilities in Europe

Ardelyx reports positive results from tenapanor Phase 2b clinical trial in IBS-C patients

WHO Regional Office for the Eastern Mediterranean press release: WHO delivers additional medicines and medical supplies into Yemen

DaVita HealthCare Partners recognizes May as Employee Health Month

Phosphate Therapeutics reports positive results from PT20 trial in people with hyperphosphataemia

DaVita Way of Giving program receives Communitas Award

Upsher-Smith presents favorable data from PREVAIL OLE study of Qudexy XR capsules

Bayshore HealthCare achieves BPSO designation

NEFIGAN Trial of Nefecon for treatment of primary IgA nephropathy meets primary endpoint

Managing autosomal dominant polycystic kidney disease: an interview with Dr Richard Sandford, University of Cambridge

New simeprevir clinical data to be presented at EASL's International Liver Congress 2015

New oral drug shows promise in patients with chronic kidney disease

Six winners share £2 million to develop cutting-edge technology to prevent kidney disease

DaVita Kidney Care celebrates its dietitians and social workers

Regulus' RG-012 receives orphan medicinal product designation in EU for treatment of Alport syndrome

TVA Medical's novel hemodialysis access technique shows positive outcomes in clinical study

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Dialysis News and Research

Latest Dialysis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in